Andrew Plummer

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 593 citations

Treatment And Prevention, Medicine, Antiviral Drug Development +10

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2015 · 304 citations

Hiv/aids Counselling, Treatment And Prevention, Pharmacology +11

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

Joel E. Gallant, Eric S. Daar, François Raffi et al. · The Lancet HIV · 2016 · 165 citations

Treatment And Prevention, Medicine, Antiviral Drug Development +10

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection

Andrew Zolopa, Paul E. Sax, Edwin DeJesus et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 145 citations

Serum Creatinine, Week 96, Treatment And Prevention +14

Novel Framework for Assessing Epidemiologic Effects of Influenza Epidemics and Pandemics

Carrie Reed, Matthew Biggerstaff, Lyn Finelli et al. · Emerging infectious diseases · 2012 · 132 citations · Full text